shutterstock_1644459649_ascannio
Ascannio / Shutterstock.com
25 September 2020AmericasRory O'Neill

PTAB cancels Imbruvica patent claims in blow for AbbVie

The US Patent Trial and Appeal Board (PTAB) has invalidated parts of an AbbVie patent covering blood disease drug Imbruvica (ibrutinib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.

More on this story

Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.

More on this story

Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.